Search

Your search keyword '"Deau, Bénédicte"' showing total 5 results
Start Over Author "Deau, Bénédicte" Publication Year Range Last 3 years
5 results on '"Deau, Bénédicte"'

1. S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA

Author

Marouf, Amira, primary, Chaubard, Sammara, additional, Michot, Jean Marie, additional, Rossignol, Julien, additional, Golfier, Camille, additional, Allangba, Olivier, additional, Philippe, Laure, additional, Tessoulin, Benoit, additional, Chauchet, Adrien, additional, Deau, Bénédicte, additional, Oberic, Lucie, additional, Vargaftig, Jacques, additional, Moignet, Aline, additional, Clavert, Aline, additional, Duléry, Rémy, additional, Brisou, Gabriel, additional, Tardy, Stéphanie, additional, Fataccioli, Virginie, additional, Houot, Roch, additional, Olivier Casasnovas, Rene, additional, Thieblemont, Catherine, additional, Ghesquieres, Herve, additional, Carras, Sylvain, additional, Le Gouill, Steven, additional, Cartron, Guillaume, additional, Marabelle, Aurélien, additional, Tournilhac, Olivier, additional, Laurent Damaj, Gandhi, additional, Gaulard, Philippe, additional, Leval, Laurence De, additional, Lemonnier, Francois, additional, Bachy, Emmanuel, additional, Hermine, Olivier, additional, Couronné, Lucile, additional, and Jaccard, Arnaud, additional

Published
2023
Full Text
View/download PDF

2. Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

Author

Johnson-Ansah, Hyacinthe, primary, Maneglier, Benjamin, additional, Huguet, Françoise, additional, Legros, Laurence, additional, Escoffre-Barbe, Martine, additional, Gardembas, Martine, additional, Cony-Makhoul, Pascale, additional, Coiteux, Valérie, additional, Sutton, Laurent, additional, Abarah, Wajed, additional, Pouaty, Camille, additional, Pignon, Jean-Michel, additional, Choufi, Bachra, additional, Visanica, Sorin, additional, Deau, Bénédicte, additional, Morisset, Laure, additional, Cayssials, Emilie, additional, Molimard, Mathieu, additional, Bouchet, Stéphane, additional, Mahon, François-Xavier, additional, Nicolini, Franck, additional, Aegerter, Philippe, additional, Cayuela, Jean-Michel, additional, Delord, Marc, additional, Bruzzoni-Giovanelli, Heriberto, additional, and Rousselot, Philippe, additional

Published
2022
Full Text
View/download PDF

3. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline

Author

Rossi, Cédric, primary, André, Marc, additional, Dupuis, Jehan, additional, Morschhauser, Franck, additional, Joly, Bertrand, additional, Lazarovici, Julien, additional, Ghesquières, Hervé, additional, Stamatoullas, Aspasia, additional, Nicolas-Virelizier, Emmanuelle, additional, Feugier, Pierre, additional, Gac, Anne-Claire, additional, Moatti, Hannah, additional, Fornecker, Luc-Matthieu, additional, Deau, Bénédicte, additional, Joubert, Clémentine, additional, Fortpied, Catherine, additional, Raemaekers, John, additional, Federico, Massimo, additional, Kanoun, Salim, additional, Meignan, Michel, additional, Traverse-Glehen, Alexandra, additional, Cottereau, Anne-Ségolène, additional, and Casasnova, René-Olivier, additional

Published
2022
Full Text
View/download PDF

4. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline

Author

Rossi, Cédric, André, Marc, Dupuis, Jehan, Morschhauser, Franck, Joly, Bertrand, Lazarovici, Julien, Ghesquières, Hervé, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Gac, Anne-Claire, Moatti, Hannah, Fornecker, Luc-Matthieu, Deau, Bénédicte, Joubert, Clémentine, Fortpied, Catherine, Raemaekers, John, Federico, Massimo, Kanoun, Salim, Meignan, Michel, Traverse-Glehen, Alexandra, Cottereau, Anne-Ségolène, Casasnovas, René-Olivier, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie

Abstract

Stage IIB Hodgkin lymphoma (HL) patients, with a mediastinum-to-thorax (M/T) ratio of ≥0.33 or extranodal localization have a poor prognosis and are treated either as limited or advanced stage. We compared these two approaches in patients included in two randomized phase III trials enrolling previously untreated early (H10) or advanced stage HL (AHL2011). We included HL patients with Ann-Arbor stage IIB with M/T ≥0.33 or extranodal involvement enrolled in the H10 or AHL2011 trials with available PET at baseline and after two cycles of chemotherapy (PET2). Baseline total metabolic tumor volume (TMTV) was calculated using the 41% SUVmax method. PET2 response assessment used the Deauville score. 148 patients were eligible, including 83 enrolled in the AHL2011 trial and 65 in the H10 trial. The median TMTV value was 155.5 mL (8.3-782.9), 165.6 mL in AHL2011 and 147 mL in H10. PET2 positivity rates were 16.9% (n=14) and 9.2% (n=6) in AHL2011 and H10 patients, respectively. With a median follow-up of 4.1 years (95%CI 3.9-4.4), overall 4-year PFS was 88.0%, 87.0% in AHL2011 and 89.2% in H10. In univariate and mutivariate analyses, baseline TMTV and PET2 response influenced significantly PFS (HR=4.94, HR=3.49 respectively). Notably, among the 16 patients who relapsed, 13 (81%) had a baseline TMTV baseline ≥ 155 mL. Upfront ABVD plus radiation therapy or upfront escBEACOPP without radiotherapy provide similar patient's outcome in high-risk stage IIB HL. TMTV is useful to stratify these patients at baseline.

Published
2022

5. Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5‐year analysis of the French early access program (EPA).

Author

Manson, Guillaume, Herbaux, Charles, Schiano, Jean‐Marc, Casasnovas, Olivier, Stamatoullas, Aspasia, Deau, Bénédicte, Schmitt, Anna, Regny, Caroline, Bouabdallah, Krimo, Chauchet, Adrien, Ghesquieres, Hervé, Tempescul, Adrian, Dulery, Remy, Nicolas‐Virelizier, Emmanuelle, Delmer, Alain, Borel, Cecile, Dercle, Laurent, Brice, Pauline, and Houot, Roch

Subjects
HODGKIN'S disease, DISEASE relapse, NIVOLUMAB, HEMATOPOIETIC stem cell transplantation
Abstract

The study included patients with HL relapsing or refractory after three lines of chemotherapy (including brentuximab-vedotin) and autoHSCT, or four lines of chemotherapy if the patient was not eligible for HSCT. To assess whether some patients might be cured with nivolumab alone as systemic treatment, we analysed the 19 patients who achieved a CR and did not receive a consolidation (concomitant radiotherapy was performed in five patients). Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma?. [Extracted from the article]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results